| P50 | author | Nandi Siegfried | Q28039178 |
| P2093 | author name string | Alicen Spaulding | |
| | George W Rutherford | |
| | James H Irlam | |
| | Lawrence CE Mbuagbaw | |
| P2860 | cites work | Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults | Q24246038 |
| | The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes | Q24627714 |
| | Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 | Q24802369 |
| | GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 |
| | Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 |
| | Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine | Q61895315 |
| | Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002) | Q81285277 |
| | Imputing missing standard deviations in meta-analyses can provide accurate results | Q29620610 |
| | HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study | Q33429719 |
| | The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. | Q34402447 |
| | Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study | Q34546335 |
| | Genetic mechanisms of resistance to NRTI and NNRTI. | Q34658625 |
| | Genetic mechanisms of resistance to protease inhibitors and entry inhibitors | Q34658632 |
| | Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine | Q35097400 |
| | Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. | Q36285950 |
| | Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review | Q36738171 |
| | Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults | Q37137838 |
| | Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 |
| | The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals | Q38450995 |
| | A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study | Q42170053 |
| | Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection | Q42990738 |
| | High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals | Q43646768 |
| | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy | Q43818117 |
| | Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study | Q43820991 |
| | Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors | Q43935752 |
| | Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study | Q44108848 |
| | Decline in deaths from AIDS due to new antiretrovirals | Q44184848 |
| | Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs | Q44198482 |
| | Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin | Q44386599 |
| | Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients | Q44660478 |
| | Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection | Q44794035 |
| | Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 |
| | Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children | Q45010903 |
| | Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects | Q45270618 |
| | Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz | Q45279098 |
| | Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy | Q45383777 |
| | Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. | Q45398049 |
| | Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less | Q46150625 |
| | A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India | Q46173768 |
| | Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. | Q46269343 |
| | Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy | Q46447967 |
| | Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). | Q46559774 |
| | Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients | Q46571863 |
| | Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. | Q46807885 |
| | Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine | Q46923095 |
| | Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. | Q51777826 |
| | The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. | Q52065697 |
| | Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy | Q61895314 |
| P921 | main subject | nevirapine | Q263713 |
| | efavirenz | Q422645 |
| | anti-retroviral agent | Q50430310 |
| P577 | publication date | 2010-12-08 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals | |